Lower-Risk Myelodysplastic Syndrome (MDS) Clinical Trial
Now Enrolling

A clinical study to evaluate the safety and efficacy of RVT-2001, an oral investigational medication, in patients with lower-risk MDS who are transfusion dependent

Select Eligibility Criteria

- Lower-risk MDS
- Carry a SF3B1 mutation
- Red blood cell transfusion dependent

- No prior lenalidomide or hypomethylating agents such as azacytidine or decitabine
- Failed or refractory to erythropoiesis stimulating agents
- Be at least 18 years old

If you are interested in participating in this trial, please talk to your doctor about your eligibility and further details about the study

For more information, visit clinicaltrials.gov and search NCT02841540

RVT-2001 is an investigational drug that is not approved by the FDA or any other global health authority in MDS. Safety and efficacy have not been established in MDS.

Study Design: Dose-optimization

Patient may continue treatment until disease progression

Screening: To assess if patient qualifies to participate (up to 28 days)

Group 1: Twice daily dosing RVT-2001 (N= up to 32)

Group 2: Once daily dosing RVT-2001 (N= up to 32)

Optional Group 3 based on safety and tolerability